The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
6-chloro-N-(1-(2-chloroacetyl)pyrrolidin-3-yl)-7-iodo-4-oxo-1,4-dihydroquinoline-2-carboxamide ID: ALA5278066
Max Phase: Preclinical
Molecular Formula: C16H14Cl2IN3O3
Molecular Weight: 494.12
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: O=C(NC1CCN(C(=O)CCl)C1)c1cc(=O)c2cc(Cl)c(I)cc2[nH]1
Standard InChI: InChI=1S/C16H14Cl2IN3O3/c17-6-15(24)22-2-1-8(7-22)20-16(25)13-5-14(23)9-3-10(18)11(19)4-12(9)21-13/h3-5,8H,1-2,6-7H2,(H,20,25)(H,21,23)
Standard InChI Key: UWXHPPZSMIHWRD-UHFFFAOYSA-N
Molfile:
RDKit 2D
25 27 0 0 0 0 0 0 0 0999 V2000
-3.8266 0.4956 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.1121 0.9079 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4002 0.4960 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4002 -0.3291 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.1102 -0.7409 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8266 -0.3328 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.6855 -0.7416 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.9709 -0.3291 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.2562 -0.7416 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4583 -0.3291 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.1729 -0.7416 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.6855 0.9086 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.9709 0.4960 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.6855 1.7338 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.2562 -1.5669 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.9264 -0.4062 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4783 -1.0191 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.0659 -1.7334 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2591 -1.5619 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.5413 0.9082 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
-4.5413 -0.7453 0.0000 I 0 0 0 0 0 0 0 0 0 0 0 0
3.3035 -1.0191 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.7161 -0.3045 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.7161 -1.7338 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.5413 -1.7338 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
1 6 1 0
6 5 2 0
4 7 1 0
7 8 1 0
8 9 1 0
9 10 1 0
11 10 1 0
3 12 1 0
12 13 1 0
8 13 2 0
12 14 2 0
9 15 2 0
16 11 1 0
16 17 1 0
17 18 1 0
18 19 1 0
19 11 1 0
1 20 1 0
6 21 1 0
17 22 1 0
22 23 2 0
22 24 1 0
24 25 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 494.12Molecular Weight (Monoisotopic): 492.9457AlogP: 2.36#Rotatable Bonds: 3Polar Surface Area: 82.27Molecular Species: NEUTRALHBA: 3HBD: 2#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 11.82CX Basic pKa: ┄CX LogP: 2.26CX LogD: 2.26Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.51Np Likeness Score: -1.39
References 1. Cheng R, Lv X, Bu H, Xu Q, Wu J, Xie K, Tang J, Wang L, Zhuang J, Zhang Y, Zhang Y, Yan C, Lai Y.. (2022) Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRASG12C inhibitors with potent antitumor activity against KRAS-mutant non-small cell lung cancer., 244 [PMID:36228411 ] [10.1016/j.ejmech.2022.114808 ]